EUVIMEDEUVIMED entdecken
Crossref

Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study

Nadia Haddy, Hugo Jourdain, David Desplas, Marion Bertrand, Marie-Joelle Jabagi, Claire Rives-Lange, Mahmoud Zureik

BioDrugs · 2025

DOI: 10.1007/s40259-024-00699-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioDrugs, 2025. Verfasst von Nadia Haddy und 6 weiteren Autor:innen. Beteiligte Einrichtung: EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products - ANSM…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Drug Utilization, Obesity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide 1 receptor agonists have shown promising results in obesity treatment. In France, semaglutide 2.4-mg (Wegovy) has benefited from an early-access program from July 2022 to September 2023. OBJECTIVE: This study aimed to describe the user profile of semaglutide 2.4-mg and the dosage patterns under real-world conditions during this period. METHODS: Between July 2022 and September 2023, semaglutide 2.4-mg initiators were identified through the nationwide APMO database (Accès Précoce-Médicaments Onéreux), built from the French National Health Data System (SNDS). The cohort was followed up until 31 December 2023. A sequence analysis was used to build clusters of dose escalation regimens. RESULTS: Among the 6990 adult patients who started treatment, the median age was 49.0 years, with a majority of women (65.8%). The study revealed significant regional variations in initiation rates, with the highest in Ile-de-France (including Paris). Three groups of users were identified: standard adherence (74.5%), early discontinuation (13.0%), and high-dose initiation (12.5%). Factors influencing these clusters included age, with younger patients (25-34 years) more likely to discontinue early (odds ratio: 1.35 [95% confidence interval 1.05-1.75]). The use of anti-emetics during the first 5 months of the follow-up period was higher in the early-discontinuation group (15.7%) compared with the high-dose initiation group (9.0%) and standard adherence group (12.3%). CONCLUSIONS: This study involved a substantial number of real-life semaglutide 2.4-mg users and highlights the importance of monitoring treated patients from a public health perspective, given the broad prescription to come and the potential risks associated with misuse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDrug UtilizationObesityHumansFranceFemaleMiddle AgedMaleAdultAgedGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like PeptidesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France. nadia…
  • EPIPHARE Scientific Interest Group in Epidemiology of Health Products, (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
  • UMR1346, Université Paris Cité, Inria, INSERM, Paris, France.

Zitieren

APA

Haddy, N., Jourdain, H., Desplas, D., Bertrand, M., Jabagi, M. J., Rives-Lange, C., & Zureik, M. (2025). Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study. BioDrugs. https://doi.org/10.1007/s40259-024-00699-6

Vancouver

Haddy N, Jourdain H, Desplas D, Bertrand M, Jabagi MJ, Rives-Lange C, et al. Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study. BioDrugs. 2025. doi:10.1007/s40259-024-00699-6

BibTeX
@article{Haddy2025,
  author = {Haddy, Nadia and Jourdain, Hugo and Desplas, David and Bertrand, Marion and Jabagi, Marie-Joelle and Rives-Lange, Claire and Zureik, Mahmoud},
  title = {Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study},
  journal = {BioDrugs},
  year = {2025},
  doi = {10.1007/s40259-024-00699-6}
}
Kostenlos starten →